Aurobindo Pharma Forms New Subsidiary Avogent Lifesciences

's wholly owned subsidiary, Apitoria Pharma Private Limited, has incorporated a new wholly owned step-down subsidiary named Avogent Lifesciences Private Limited in India. The new entity, formed on August 31, 2026, with an initial capital of ₹5 crore, will engage in pharmaceutical manufacturing and marketing operations across domestic and international markets. The incorporation of Avogent Lifesciences under Apitoria Pharma, which recently completed a successful US FDA inspection at its Unit-VI in late August 2026, signals a calculated move to expand global manufacturing capabilities. This allows Aurobindo Pharma to run dedicated niche marketing or manufacturing operations under a separate structure, isolating operational risk and streamlining the launch of new products in international markets. Aurobindo's continuous expansion through subsidiaries like Avogent, coupled with strategic acquisitions like Lannett, underscores its long-term vision of becoming a vertically integrated global pharma powerhouse with a diversified risk profile. Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations.